YU68602A - Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje - Google Patents

Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje

Info

Publication number
YU68602A
YU68602A YU68602A YUP68602A YU68602A YU 68602 A YU68602 A YU 68602A YU 68602 A YU68602 A YU 68602A YU P68602 A YUP68602 A YU P68602A YU 68602 A YU68602 A YU 68602A
Authority
YU
Yugoslavia
Prior art keywords
monoclonal antibodies
production
ldl receptor
human ldl
human
Prior art date
Application number
YU68602A
Other languages
English (en)
Inventor
Nachum Yonah
Dany Suissa
Ilana Belzer
Francesco Antonetti
Moshe Smolarsky
Michael Dreano
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26323933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU68602(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL13502500A external-priority patent/IL135025A0/xx
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of YU68602A publication Critical patent/YU68602A/sh
Publication of RS51406B publication Critical patent/RS51406B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Ovde su data monoklonska antitela na LDL receptor koja su korisna za identifikaciju i prečišćavanje LDL kao i u lečenju, na primer infekcije virusom hepatitis C.[There are provided monoclonal antibodies to the human LDL receptor which are useful for the identification and purification of LDL and in treatment of e.g. hepatitis C infection.
YUP-686/02A 2000-03-13 2001-03-08 Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje RS51406B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL13502500A IL135025A0 (en) 2000-03-13 2000-03-13 Monoclonal antibodies to the human ldl receptor, their production and use
IL13921700A IL139217A0 (en) 2000-03-13 2000-10-23 Monoclonal antibodies to the human ldl receptor, their production and use
PCT/IL2001/000216 WO2001068710A1 (en) 2000-03-13 2001-03-08 Monoclonal antibodies to the human ldl receptor, their production and use

Publications (2)

Publication Number Publication Date
YU68602A true YU68602A (sh) 2006-03-03
RS51406B RS51406B (sr) 2011-02-28

Family

ID=26323933

Country Status (33)

Country Link
US (1) US6849720B2 (sh)
EP (1) EP1263790B1 (sh)
JP (1) JP4768193B2 (sh)
KR (1) KR100882081B1 (sh)
CN (1) CN1418225B (sh)
AR (1) AR028518A1 (sh)
AT (1) ATE362490T1 (sh)
AU (2) AU4100201A (sh)
BG (1) BG65762B1 (sh)
BR (1) BR0109164A (sh)
CA (1) CA2402593C (sh)
CY (1) CY1108020T1 (sh)
CZ (1) CZ20023098A3 (sh)
DE (1) DE60128452T2 (sh)
DK (1) DK1263790T3 (sh)
EA (1) EA007494B1 (sh)
EE (1) EE200200517A (sh)
ES (1) ES2282238T3 (sh)
HK (1) HK1055750A1 (sh)
HR (1) HRP20020704B1 (sh)
HU (1) HU226194B1 (sh)
IL (2) IL139217A0 (sh)
MX (1) MXPA02009091A (sh)
NO (1) NO330904B1 (sh)
NZ (1) NZ520944A (sh)
PL (1) PL206041B1 (sh)
PT (1) PT1263790E (sh)
RS (1) RS51406B (sh)
SI (1) SI1263790T1 (sh)
SK (1) SK287348B6 (sh)
UA (1) UA78489C2 (sh)
WO (1) WO2001068710A1 (sh)
ZA (1) ZA200206654B (sh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114629D0 (en) * 2001-06-15 2001-08-08 Pfizer Ltd Method
ES2401645T3 (es) 2003-06-19 2013-04-23 Merck Serono Sa Uso de agentes moduladores de la conversión de priones
FR2889532B1 (fr) * 2005-08-03 2007-10-12 Lab Francais Du Fractionnement Anticorps diriges contre le recepteur du ldl
FR2889533B1 (fr) * 2005-08-03 2007-10-12 Lab Francais Du Fractionnement Anticorps diriges contre le recepteur du ldl
US20090305258A1 (en) * 2006-02-17 2009-12-10 Paolo La Colla Methods for the diagnosis of proliferative and/or conformational diseases
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
IL182956A0 (en) 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
IL188628A0 (en) * 2008-01-07 2008-12-29 Yeda Res & Dev Use of soluble ldl-r for viral hepatitis
GB0922377D0 (en) * 2009-12-22 2010-02-03 Arab Gulf University The Mutant LDL receptor
EP2575885A1 (en) 2010-05-25 2013-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024157A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of host targeting agents for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
CN103111270B (zh) * 2013-02-26 2015-06-10 王业富 一种乙型肝炎抗原蛋白的吸附材料及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182364A (en) * 1990-02-26 1993-01-26 The Scripps Research Institute Polypeptide analogs of apolipoprotein E
US5496926A (en) * 1992-01-19 1996-03-05 Yeda Research And Development Co. Ltd. Process of preparing a soluble LDL receptor
US5945308A (en) * 1998-04-03 1999-08-31 Incyte Pharmaceuticals, Inc. Human oxidized LDL receptor
JP2000279174A (ja) * 1999-03-30 2000-10-10 Bml Inc ヒトｌｄｌレセプターに対するモノクローナル抗体及びこれを用いる家族性高脂血症の判定方法

Also Published As

Publication number Publication date
CA2402593C (en) 2012-07-03
IL139217A0 (en) 2001-11-25
DK1263790T3 (da) 2007-07-02
DE60128452T2 (de) 2007-09-13
EP1263790B1 (en) 2007-05-16
NO20024223D0 (no) 2002-09-04
EP1263790A1 (en) 2002-12-11
PL358381A1 (en) 2004-08-09
HU226194B1 (hu) 2008-06-30
KR20020089384A (ko) 2002-11-29
PT1263790E (pt) 2007-06-01
HUP0300142A3 (en) 2005-07-28
NO20024223L (no) 2002-10-24
SK13122002A3 (sk) 2003-04-01
BG65762B1 (bg) 2009-10-30
BR0109164A (pt) 2002-11-26
UA78489C2 (en) 2007-04-10
RS51406B (sr) 2011-02-28
PL206041B1 (pl) 2010-06-30
ATE362490T1 (de) 2007-06-15
MXPA02009091A (es) 2005-06-20
AU2001241002B8 (en) 2006-05-04
CZ20023098A3 (cs) 2003-02-12
BG107063A (bg) 2003-05-30
AU4100201A (en) 2001-09-24
US6849720B2 (en) 2005-02-01
WO2001068710A1 (en) 2001-09-20
CN1418225B (zh) 2012-04-18
JP4768193B2 (ja) 2011-09-07
DE60128452D1 (de) 2007-06-28
CY1108020T1 (el) 2013-09-04
EE200200517A (et) 2004-02-16
IL151713A0 (en) 2003-04-10
HUP0300142A2 (hu) 2003-06-28
US20030186343A1 (en) 2003-10-02
SI1263790T1 (sl) 2007-10-31
ES2282238T3 (es) 2007-10-16
AR028518A1 (es) 2003-05-14
JP2004506603A (ja) 2004-03-04
EA200200974A1 (ru) 2003-02-27
HRP20020704A2 (en) 2004-12-31
CN1418225A (zh) 2003-05-14
HK1055750A1 (en) 2004-01-21
NZ520944A (en) 2004-04-30
NO330904B1 (no) 2011-08-15
EA007494B1 (ru) 2006-10-27
ZA200206654B (en) 2003-10-20
HRP20020704B1 (en) 2011-01-31
AU2001241002B2 (en) 2006-04-06
CA2402593A1 (en) 2001-09-20
SK287348B6 (sk) 2010-08-09
KR100882081B1 (ko) 2009-02-10

Similar Documents

Publication Publication Date Title
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
EP1194164B8 (en) Prion protein peptides and uses thereof
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
MXPA03001590A (es) Anticuerpos para la il-1beta humana.
PT1157042E (pt) Produção de anticorpos tetravalentes
TR200602095T2 (tr) Hümanize Anti-LT-Beta-R antikorları
DE60137631D1 (de) Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
MXPA04005079A (es) Variantes del dominio c2 del factor viii.
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
EP1370697A4 (en) PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE
DE60005526D1 (de) Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes
DK1299350T3 (da) Substituerede benzamider til styrket immunforsvar og behandling af kræft, infektioner og manio-depressive sygdomme